Shares of Torrent Pharmaceuticals rallied more than 4% during Monday’s trading session and touched a fresh 52-week high despite the company reporting a year-on-year decline in fourth-quarter net profit.
The stock gained 4.11% to ₹4,670.60 on the NSE and hit a new 52-week high of ₹4,681 during intraday trade. Around 9:57 AM, the stock was trading higher by ₹184.40 as investors reacted positively to strong revenue growth, healthy operating performance, and continued momentum across domestic and global markets.
Torrent Pharma Q4 FY26 Results
Torrent Pharmaceuticals reported a consolidated net profit of ₹389 crore for the quarter ended March 2026, down 21.9% compared to ₹498 crore reported in the corresponding quarter last year.
Despite the decline in profitability, the company posted strong growth in revenue and operating earnings.
Revenue from operations surged 41.8% year-on-year to ₹4,197 crore against ₹2,959 crore in Q4 FY25. EBITDA rose 40.7% to ₹1,356 crore compared to ₹964 crore in the year-ago period.
EBITDA margin came in at 32% versus 33% in the corresponding quarter last year.
India Business Continues Strong Growth Momentum
Torrent Pharma’s India business remained the key growth driver during the quarter.
Revenue from the domestic market increased 43% year-on-year to ₹2,215 crore. The company stated that its base business registered 15% growth, outperforming the Indian Pharmaceutical Market growth of 10%, according to AIOCD PharmaTrac data.
The company also highlighted strong traction in its chronic therapies portfolio and continued market share gains across key segments.
International Markets Deliver Healthy Performance
Torrent Pharmaceuticals reported robust growth across major international markets during the quarter.
Brazil revenues increased 30% year-on-year to ₹455 crore, while US revenues rose 31% to ₹396 crore.
Germany revenues climbed 16% to ₹333 crore despite supply disruptions faced by a third-party supplier.
The company further highlighted the strong launch performance of Gx Semaglutide, which secured a 38% market share across oral and injectable formats, according to April 2026 PharmaTrac data.
Fundraising Plan and Dividend Announcement
Torrent Pharmaceuticals has sought shareholder approval to raise up to ₹5,000 crore through equity issuance, including Qualified Institutional Placement (QIP) and convertible instruments.
The board has also recommended a final dividend of ₹9 per equity share for FY26. Earlier during the financial year, the company had already paid an interim dividend of ₹29 per share.
Brokerage View
Global brokerage firm Jefferies signalled a “Buy” rating on Torrent Pharma with a target price of ₹5,350.
According to the brokerage, the March quarter included two months of JB Pharma integration, and on a like-for-like basis, the company’s performance remained broadly in line with estimates. Jefferies also noted that the India business continued to maintain strong growth momentum and management expects FY27 performance to remain similar or better.
Disclaimer: This article is for informational purposes only and should not be considered as investment advice. Investors are advised to consult certified financial advisors before making any investment decisions. Stock market investments are subject to market risks, and past performance does not guarantee future returns. The views and data mentioned are based on publicly available information and company filings.